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Alterations to the Gastrointestinal 
Microbiome Associated with 
Methamphetamine Use among 
Young Men who have Sex with Men
Ryan R. cook  1, Jennifer A. fulcher2,3, nicole H. tobin4, fan Li4, David J. Lee4, 
cora Woodward4, Marjan Javanbakht1, Ron Brookmeyer5, Steve Shoptaw6,7, Robert Bolan8,9, 
Grace M. Aldrovandi4 & pamina M. Gorbach1
Methamphetamine (MA) use is a major public health problem in the United States, especially among 
people living with HIV (PLWH). Many MA-induced neurotoxic effects are mediated by inflammation 
and gut microbiota may play a role in this process, yet the effects of MA on the microbiome have 
not been adequately explored. Therefore, we performed 16S rRNA gene sequencing on rectal swab 
samples from 381 men who have sex with men, 48% of whom were PLWH and 41% of whom used MA. 
We compared microbiome composition between MA users and non-users while testing for potential 
interactions with HiV and controlling for numerous confounders using inverse probability of treatment 
weighting. We found that MA use explained significant variation in overall composition (R2 = 0.005, 
p = 0.008) and was associated with elevated Finegoldia, Parvimonas, Peptoniphilus, and Porphyromonas 
and reduced Butyricicoccus and Faecalibacterium, among others. Genera including Actinomyces and 
Streptobacillus interacted with HiV status, such that they were increased in HiV+ MA users. Finegoldia 
and Peptoniphilus increased with increasing frequency of MA use, among others. in summary, MA use 
was associated with a microbial imbalance favoring pro-inflammatory bacteria, including some with 
neuroactive potential and others that have previously been associated with poor HiV outcomes.
The 2017 National Survey on Drug Use and Health estimated that nearly one million people in the United States 
were current users of methamphetamine (MA) or had a MA use disorder in the past year1. MA use is a major pub-
lic health concern with myriad negative health consequences ranging from anxiety and confusion to psychosis 
and violent behavior; chronic abuse may even result in severe and lasting structural changes in the brain affecting 
emotional regulation and cognition2. MA use is much more prevalent among people living with HIV, with rates 
of recent use 30 times higher and rates of dependence 33 times higher than the general population (0.3% vs. 9% 
recent use and 0.4% vs. 13% dependence)1,3,4. MA increases susceptibility to HIV infection by altering immune 
activity5,6 inhibiting neurocognitive processes involved in judgement and decision-making7 and increasing the 
frequency of risky sex acts4,8. MA use among people living with HIV is associated with reduced likelihood of 
achieving viral suppression9, faster disease progression10, and increased risk of transmission to others11.
Many MA-induced neurotoxic effects are mediated by inflammation5,12, and the microbiome, which is 
involved in inducing and regulating the immune system13, may play a role in this process. Exposure to MA 
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impacts both innate and adaptive immunity, increasing production of inflammatory cytokines, inhibiting T-cell 
proliferation, altering gene expression of immune cells, modifying cytokine signaling pathways, and increasing 
blood-brain barrier permeability5,14,15. MA damages gut wall integrity and increases intestinal permeability lead-
ing to the translocation of microbiota into the body15. This process disrupts symbiotic interactions between the 
host immune system and microbiota, inducing an immune response that may cyclically exacerbate intestinal per-
meability and further inflammation16. Microbial translocation has been cited as one of the key drivers of chronic 
inflammation described in many other diseases, including HIV, and may play a similar role in MA-induced 
inflammation and toxicity. Furthermore, mediated by inflammation, disruption of gut bacterial communities 
(termed “dysbiosis”) may be a mechanistic link between methamphetamine use and HIV transmission and dis-
ease progression.
Dysbiosis has been described in individuals with substance use disorders17, chronic prescription opioid18 and 
cocaine users19, as well as people living with HIV20 and those practicing anal intercourse21. We recently showed 
that MA use was associated with microbiome changes in a small sample of HIV-infected MSM22. However, no 
large studies into the effects of MA on the microbiome have been completed, and no studies have examined the 
potential role of HIV in MA-induced dysbiosis. In order to address this gap, we studied the effects of MA on 
the gastrointestinal microbiome in a cohort of young men who have sex with men (MSM), approximately half 
of whom were HIV-infected, and all of whom were engaging in anal intercourse. We hypothesized that MA use 
would be associated with increased relative abundance of pro-inflammatory and pathogenic bacterial taxa as 
well as alterations to those with neurologic effects. We also hypothesized that MA use and HIV would interact to 
increase the severity of dysbiosis.
Materials and Methods
Study population. Specimens and data for this study were drawn from a larger cohort, the NIDA-funded 
Minority Men who have Sex with Men Cohort at UCLA Linking Infections Noting Effects (MASCULINE, or 
mSTUDY). Subject selection procedures have been previously described23. Briefly, participants were all men born 
males, aged 18–45, with approximately one-half of the sample purposefully included due to current substance use 
(the other half non-substance users) and one-half of the sample purposefully included due to HIV-infection (the 
other half being HIV-negative). The mSTUDY was approved by the UCLA South General Institutional Review 
Board (IRB), and the current study was approved by the UCLA Medical IRB 1. All participants provided written 
informed consent prior to participation and all study procedures were done in accordance with ethical principles 
for human subjects research.
Specimen collection and DnA preparation. As previously described23, samples included in this study 
were rectal swabs (FLOQSwabs, Copan Diagnostics, Murrieta, CA). The majority (76%) were collected via anos-
copy under direct mucosal visualization and without preparatory enema at approximately 8 cm from the anal 
verge. Due to a protocol change, others (24%) were participant self-collected at approximately 4–5 cm from the 
anal verge. Collection method was taken into account in the analysis (Table 1; Supplemental content). Swabs were 
immediately frozen neat at −80 °C until processing in bulk. For DNA processing the samples were transferred to 
Lysing Matrix E tubes (MP Biomedicals, Burlingame, CA) containing RLT lysis buffer (Qiagen, Hilden, Germany) 
and bead-beated on a TissueLyser (Qiagen). DNA was then extracted using the AllPrep DNA/RNA/Protein kit 
(Qiagen) per manufacturer’s protocol.
16S rRNA gene sequencing and data processing. Microbiome profiling was performed by sequenc-
ing of the V4 region of the 16S rRNA gene as previously described23–25. Briefly, the V4 region was amplified in 
triplicate reactions using Golay-barcoded primers 515F/806R. PCR products were then pooled and sequenced 
on the Illumina MiSeq platform using 2 × 150 bp v2 chemistry. The sequences were demultiplexed with Golay 
error correction using QIIME v1.9.126, and Divisive Amplicon Denoising Algorithm (DADA2) version 1.8 was 
used for error correction, exact sequence inference, read merging, and chimera removal27. The resultant ampli-
con sequence variant (ASV) table comprised 19,955,039 total merged read pairs (mean per sample = 52,375; 
range 10,906 to 124,889). Taxonomic assignment was performed using RDP trainset 16 (https://doi.org/10.5281/
zenodo.810827). Rarefaction was performed at a depth of 10,906 reads for alpha diversity analyses. To normalize 
all other analyses, estimates of relative library sizes (“size factors”) were obtained by calculating geometric means 
of pairwise read count ratios28.
Measurement of MA use. MA use was measured using an adapted version of the NIDA-modified 
ASSIST29. Participants were asked how often they used MA in the previous six months; response choices were 
“Daily”, “Weekly”, “Monthly”, “Less often”, “Once”, and “Never.” For most analyses we categorized participants 
as MA users if they indicated any use in the past six months, and non-users if they responded “Never.” For the 
dose-response analysis, we combined “Monthly”, “Less often”, and “Once” into “Monthly or less often,” given that 
infrequent exposures are likely to have similar effects on the microbiome. In addition, participants were screened 
for MA use via urinalysis [Fastect® II (Branan Medical Corporation); iScreen® Dip Card (Alere)]. We did not use 
the urinalysis results as our primary exposure variable because the detection window for MA is 48–72 hours and 
no exposure quantification (and thus dose-response analysis) could be done. We instead compared the self-report 
and urinalysis results as a sensitivity analysis (Supplementary Figs S4, S5 and S6). HIV status was ascertained 
upon entry into the cohort by medical record review (for known HIV-infected participants) or the OraQuick 
Advance® HIV 1/2 (OraSure Technologies, Bethlehem, PA).
Behavioral and clinical covariates. Analyses controlled for a large set of behavioral and clinical covariates 
including age, race/ethnicity, homelessness in past six months, number of receptive anal intercourse (RAI) acts 
in past month, number of anal sex partners in past six months, an indicator for RAI in the past seven days, an 
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indicator for a positive STI test (including PCR tests for rectal gonorrhea and chlamydia and serology for primary 
or secondary syphilis), self-reported use of marijuana and cocaine, tobacco smoking, and binge drinking (defined 
as 6+ drinks on more than one occasion) in the past six months, and use of antibiotics in the past month. We also 
controlled for type of antiretroviral therapy (including use of pre-exposure prophylaxis if HIV−) and an indicator 
for CD4 cell count <200 (Table 1). Measures and assays have been previously described23.
Statistical analyses. We compared clinical and behavioral characteristics between MA users and non-users 
using descriptive statistics, Wilcoxon or Chi-square tests, and standardized mean differences (see Table 1; 
Supplemental content). All analyses of microbiome outcomes were adjusted for clinical and behavioral confound-
ers using inverse probability of treatment weighting (IPTW). IPTW is a technique in which the study sample is 
re-weighted to achieve balance between exposure groups (here, MA users vs. non-users) on important covar-
iates so that their confounding effects are substantially reduced30. Covariates included in the IPTW model are 
listed in Table 1, and further information about the IPTW calculation and adjustment process is available in the 
MA- negative n = 225 
mean (sd), median n (%)
MA-positive 
n = 156 Pd
SMDe (pre, 
post IPTW)
Age 30.17 (6.85), 29 32.58 (6.75), 33 <0.001 0.35, 0.16
HIV+ 80 (35.6) 102 (65.4) <0.001 N/A
Race/ethnicity 0.6 0.1, 0.07
Black-Non Hispanic 93 (41.3) 57 (36.5)
Hispanic 107 (47.6) 79 (50.6)
Other-Non Hispanic 25 (11.1) 20 (12.8)
Homeless in past 6 months 52 (23.1) 77 (49.4) <0.001 0.57, 0.28
Had RAI in last 7 days 102 (45.3) 65 (41.7) 0.5 0.07, 0.03
Number of RAI acts in past month 2.09 (4.94), 0 2.88 (5.33), 1 <0.001 0.15, 0.03
Number of anal sex partners in past 6 months 6.17 (7.60), 3 8.79 (9.28), 5 <0.001 0.31, 0.18
Positive for STIa 19 (8.4) 28 (17.9) 0.006 0.28, 0.18
Marijuana use in past 6 months 0.1 0.23, 0.21
Daily/Weekly 69 (30.7) 60 (38.5)
Monthly/less 52 (23.1) 41 (26.3)
Never 104 (46.2) 55 (35.3)
Cocaine use in past 6 months 40 (17.8) 60 (38.5) <0.001 0.47, 0.24
Tobacco smoker 73 (32.4) 95 (60.9) <0.001 0.6, 0.38
Binge drinking in past 6 monthsb 138 (61.3) 91 (58.3) 0.6 0.06, 0.04
Antibiotic use in past month 15 (6.7) 16 (10.3) 0.2 0.13, 0.07
Sample collection strategy 0.5 0.07, 0.01
Anoscopy 169 (75.1) 122 (78.2)
Self-collected 56 (24.9) 34 (21.8)
Type of ART <0.001 0.56, 0.28
INSTI + NRTI 30 (13.3) 39 (25.0)
NNRTI + NRTI 25 (11.1) 23 (14.7)
NRTI + PI 15 (6.7) 15 (9.6)
Other 4 (1.8) 12 (7.7)
HIV+ and missing ART data 6 (2.7) 14 (9.0)
HIV− pre-exposure prophylaxis (PrEP) user 30 (13.3) 7 (4.5)
HIV−, no PrEP 115 (51.1) 47 (30.1)
Among HIV+ participants only
HIV RNA log10 copies/mL (median, IQR) c 1.03 (0.7) 1.03 (1.7) N/A
CD4 cells/mm3 (median, IQR)c 590.5 (267) 635 (424.3) N/A
CD4 cells/mm3 <200 5 (2.2) 9 (5.8) 0.18, 0.15
Table 1. Participant characteristics, N = 381 men who have sex with men in Los Angeles, CA. 
MA = Methamphetamine; SMD = Standardized mean difference; RAI = Receptive anal intercourse; 
STI = Sexually transmitted infection; ART = Antiretroviral therapy; INSTI = Integrase strand transfer inhibitor; 
NRTI = Nucleoside reverse transcriptase inhibitor; NNRTI = Non-nucleoside reverse transcriptase inhibitor; 
PI = Protease inhibitor. aSexually transmitted infections include rectal gonorrhea, rectal chlamydia as well as 
primary/secondary syphilis. bBinge drinking defined as 6 or more drinks on one occasion. cHIV status, HIV 
RNA, and continuous CD4 cell count were not included in the inverse probability of treatment weight model, all 
other variables in the table were included. HIV status was taken into account in the analyses by stratifying on it 
(if there was evidence for an interaction between MA and HIV) or conditioning on it (if there was no evidence 
for an interaction). dp values are from Wilcoxon tests or Chi-square tests. eSMD is a measure of imbalance across 
groups; higher SMDs indicate greater imbalance. Average SMD before weighting = 0.28, after weighting = 0.14.
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supplemental content as well as our previous publication23. Weights were estimated using generalized boosted 
models (R package ‘twang’31) and robust standard errors for IPTW-adjusted analyses were obtained using the 
sandwich estimator (R package ‘sandwich’32). All analyses in this study proceeded by first testing for interactions 
between MA use and HIV status using multiplicative interaction terms. An alpha level of 0.1 was used as a cutoff 
for significance of interaction tests; if significant, comparisons of MA users vs. non-users are presented stratified 
by HIV status (retaining HIV status and the interaction term in the model). If no significant interaction was 
detected, comparisons of MA users vs. non-users were completed controlling for HIV status (retaining HIV status 
as a covariate but dropping the interaction term).
The R package ‘phyloseq’33 was used to calculate distance matrices, alpha diversity metrics, and for ordination. 
Permutational multivariate ANOVA (PERMANOVA; R package ‘vegan’34) was used to test for differences in over-
all microbial composition. Cluster analysis was performed using the partitioning around mediods method with 
the optimal number of clusters chosen according to the Calinski-Harabasz statistic (R packages ‘cluster’35 and 
‘fpc’36). Logistic regression was used to assess the relationship between MA use and cluster membership. Linear 
regression was used to test for differences in alpha diversity between MA users and non-users. Zero-inflated 
negative binomial (ZINB) models were used to test for differences in individual bacterial genera between groups 
(R package ‘pscl’37). We employed a previously described model selection strategy23 to choose the optimal ZINB 
model for each genus. A pre-filtering step excluded genera appearing in less than 10% of samples as well as those 
with less than 100 total reads across all samples, resulting in 78 genera included in ZINB analyses. Dose-response 
analysis was completed by regressing bacterial counts on frequency of MA use using orthogonal polynomial cod-
ing of linear and quadratic curves. As sensitivity analyses, all analyses were repeated redefining MA use according 
to urine drug screen results (except for dose-response, owing to the qualitative nature of urine drug screening). 
Finally, we examined short-term interactions between MA use and the microbiome using a correlation analysis 
among individuals testing positive for MA on urine drug screen. Correlations were calculated with the sparCC 
method38 with bootstrapped standard errors (R package ‘SpiecEasi’39).
PERMANOVA, alpha diversity, and dose-response analyses utilized a threshold of p < 0.05 to determine sta-
tistical significance. In order to account for the large amount of genera tested, p values obtained in ZINB analyses 
and sparCC correlations were corrected using Benjamini & Hochberg’s False Discovery Rate (FDR) method40. 
FDR-adjusted p values are labelled as q values, and q < 0.1 was used as a threshold to determine statistical signifi-
cance. Accordingly, we display 90% false coverage rate (FCR)-adjusted confidence intervals41 to accompany these 
analyses. All statistical analyses were performed using R v.3.5.142 and graphics were generated with ggplot243.
Results
participant characteristics. This study included 381 participants, 156 MA users (41%) and 225 non-users 
(59%). All participants were MSM, the mean age was 31, and most were Hispanic (49%) or non-Hispanic Black 
(39%). One hundred eighty-two participants were HIV+ (48%); sixty-five percent of MA users were HIV+ as 
compared to 36% of non-users. MA users were also older than non-users, were more likely to have experienced 
homelessness, had RAI more frequently, had more anal sex partners, were more likely to have recently used 
cocaine, and were more likely to be tobacco smokers (Table 1).
Effects of MA use on overall microbial composition and diversity. PERMANOVA analyses with 
Bray-Curtis, Jaccard, and Jensen-Shannon distances did not reveal significant evidence supporting an inter-
action between MA and HIV on overall microbial composition (all p > 0.1; interaction p values supplied in 
Supplementary Table S1). Therefore, we described and compared overall composition between MA users and 
non-users while controlling for HIV status. Qualitative examination of descriptive barplots suggested increased 
Finegoldia, Fusobacterium, Peptoniphilus, Porphyromonas, Streptobacillus, and Streptococcus and decreased 
Bacteroides, Faecalibacterium, and Succinivibrio in MA users compared to non-users (Fig. 1A,B). Ordination 
of Bray-Curtis, Jaccard, and Jensen-Shannon distances by principal coordinates analyses revealed clustering by 
MA status (Fig. 2A). These findings were supported by PERMANOVA analyses showing that MA explained 
significant variation in overall microbial composition (Bray-Curtis R2 = 0.005, p = 0.008; additional results in 
Fig. 2A). Additionally, a clustering analysis using partitioning around medoids of Bray-Curtis distances revealed 
two distinct clusters in the microbiome data, which were significantly related to MA use. Adjusted for HIV status 
and our behavioral and clinical covariate set, the likelihood of classification into the second cluster was 2.24 times 
higher for MA users compared to non-users (OR = 2.24, p = 0.011, pseudo-R2 = 0.008).
No significant interactions between MA and HIV were detected in observed diversity or Chao1, Shannon, or 
Simpson indices (all p > 0.1; Supplementary Table S1), and no differences in diversity were detected between MA 
users and non-users in any metric (Fig. 2B). Despite lack of evidence for an interaction between HIV and MA 
use, we display descriptive, ordination and alpha diversity plots stratified by HIV status in Supplementary Figs S1 
and S2.
Effects of MA use on specific genera. Using ZINB models with IPTW adjustment, we found differences 
between MA users and non-users in multiple genera. For some, there was no evidence for an interaction between 
MA and HIV: Regardless of HIV status, MA users had higher levels of Finegoldia, Fusobacterium, Parvimonas, 
Peptoniphilus, Peptostreptococcus, and Porphyromonas, and lower levels of Butyricicoccus and Faecalibacterium, 
among others (all q < 0.1; Fig. 3; estimates and q values supplied in Supplementary Table S2). For four genera, a 
significant (q < 0.1; interaction q values supplied in Supplementary Table S2) interaction between HIV and MA 
was detected. Actinomyces, Mannheimia, Negativicoccus, and Streptobacillus were increased in HIV+ MA users 
compared to HIV+ non-users, but no difference was found in the absence of HIV. No genera were significant 
only in the HIV− stratum.
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Dose-response analysis of bacterial counts on increasing frequency of MA use. Of the 156 MA 
users in the study, 40 were daily users, 35 used weekly, and 81 used monthly or less often. Counts of Anaerococcus, 
Corynebacterium, Dietzia, Finegoldia, Mannheimia and Peptoniphilus increased linearly with increasing fre-
quency of MA use (q < 0.1 for test of linear trend). No significant quadratic dose-response curves were noted in 
any genera (Fig. S3).
Sensitivity analysis using urine toxicology screening to define MA use. Our findings, which were 
based on participant self-report of MA use, were consistent when we re-defined MA use using urine drug screen-
ing results. All participants completed urine drug screening, and fourteen percent of study participants (n = 52) 
tested positive for MA including 3 individuals who self-reported no MA use (49/52 who tested positive also 
self-reported using MA). One hundred seven self-reported using MA, but tested negative, likely because their last 
use was outside the drug screen window of detection. HIV+ participants were more likely to have a positive MA 
urine drug screen (21% among HIV+ vs. 7% among HIV−, p < 0.001).
In biomarker analyses, MA use was still a significant driver of variation in overall microbial composition 
(Bray-Curtis R2 = 0.008, p = 0.008), and no differences in alpha diversity were noted between MA users and 
non-users. Many of the same genera were elevated in MA users, e.g., Finegoldia, Fusobacterium, Peptoniphilus, 
Peptostreptococcus, and Porphyromonas, and elevations in Streptobacillus in the HIV+ stratum were noted in 
both analyses. Depletion in Faecalibacterium was consistent across analyses; the biomarker analysis also identi-
fied depletions in Clostridium cluster XI and Lactobacillus in MA users. Results from this sensitivity analysis are 
presented in Supplementary Figs S4–S6.
A
MA− MA+
MA− MA+
B
Acidaminococcus
Alloprevotella
Anaerococcus
Bacteroides
Bifidobacterium
Campylobacter
Catenibacterium
Clostridium_IV
Corynebacterium
Desulfovibrio
Dialister
Escherichia/Shigella
Faecalibacterium
Finegoldia
Fusobacterium
Gemmiger
Granulicatella
Megasphaera
Mitsuokella
Other
Parabacteroides
Parvimonas
Peptoniphilus
Peptostreptococcus
Porphyromonas
Prevotella
Ruminococcus
Streptobacillus
Streptococcus
Succinivibrio
Sutterella
Figure 1. Rectal microbial composition of study participants, N = 381. (A) Columns represent the relative 
composition of each subject’s microbiome at the genus level. Methamphetamine (MA) use by the subjects is 
indicated by a colored line below their composition. Subjects are ordered by the first principal coordinate of a 
Bray-Curtis pairwise distance matrix. Genera representing less than 1% of the composition on average across 
samples were combined into “Other.” (B) Average microbial composition within each MA use group. Bacterial 
genera representing less than 1% of the overall relative composition or present in less than 10% of the samples 
were grouped into “Other.”
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Finally, to examine short-term interactions between MA use and the microbiome, we performed a genera 
correlation analysis among individuals testing positive for recent MA use. Large, significant positive correlations 
were noted between Parvimonas and Campylobacter as well as Peptoniphilus and Campylobacter, among others 
(sparCC correlation >0.6 and q < 0.1). Moderate-to-large negative correlations were noted between Alloprevotella 
and Butyricicoccus as well as Parabacteroides and Campylobacter, among others (sparCC correlation < −0.4 and 
q < 0.1). Full results are presented in Supplemental Table S3 and Fig. S7.
Discussion
This study of 381 MSM who were either HIV-infected or at high risk for HIV acquisition found that MA use sig-
nificantly impacted gut microbial composition after controlling for multiple clinical and behavioral confounders. 
Measures of overall composition were altered by MA use, but measures of diversity were not, and the associa-
tions between MA and overall composition and diversity did not depend on participants’ HIV status. Several 
genera were increased in MA users regardless of HIV status, many of them considered pro-inflammatory and 
pathogenic, while others were increased among HIV+ participants only. We found that the abundance of some 
pro-inflammatory taxa increased and commensals decreased with increasing frequency of MA use. Finally, we 
were able to replicate our findings using a biomarker confirming recent MA use (urine drug screen). MA effect 
sizes were slightly larger in the biomarker analysis, likely because the window of detection for MA is short, mak-
ing frequent users more likely to test positive. Our analyses utilized a novel method of confounder control, IPTW, 
R2 = 0.005, p = 0.008 R2 = 0.004, p = 0.013 R2 = 0.006, p = 0.028
Bray−Curtis Jaccard Jensen−Shannon
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Figure 2. Associations between methamphetamine (MA) use and overall microbial composition and diversity. 
(A) Ordination of the samples using principal coordinates analysis. PCoA = Principal coordinate axis. Ellipses 
are 95% confidence regions for each group assuming points follow a multivariate t distribution. R2 and p values 
are from PERMANOVA analyses of distance metrics. (B) Boxplots of diversity metrics. Boxes represent the 
inverse probability of treatment weight-adjusted lower, median, and upper quartiles of the data and whiskers are 
1.5*interquartile range. p values are from IPTW-adjusted linear regression analyses comparing diversity metrics 
between MA users and non-users.
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to account for several factors that have previously been associated with dysbiosis (e.g. RAI21, cocaine use19, and 
alcohol use44), making our findings more likely to be truly attributable to MA use.
Although little research has been done on the effects of MA on the microbiome, our results are mostly con-
sistent with previously published literature. A study of 37 HIV+ individuals from the same cohort as the current 
data22 (none of the individuals in this current sample were included in the previous study) reported a MA effect 
size (PERMANOVA R2) of 0.1, larger than the effect we found. As in our study, there were no significant differ-
ences in diversity between MA users and non-users. Enrichment in Porphyromonas in MA users was consistent 
across studies. As a well-known modifier of inflammatory cytokines and a potential cause of intestinal permeabil-
ity45, Porphyromonas may play a role in MA-associated inflammation and deserves further investigation. Another 
study in which MA was administered to rats reported an overall effect of MA that is consistent with our findings 
(R2 of 0.008)46. This study also reported higher alpha diversity in the MA-conditioned group, which was not 
replicated in our study, and taxonomic differences that do not overlap with our findings, likely because of differ-
ences between the mouse model and a human cohort. Finally, a study comparing individuals with substance use 
disorders (SUDs) to healthy controls found a large effect of SUD (R2 of 0.067), higher observed diversity among 
individuals with SUDs, and differences in specific genera that do not match our findings17. However, participants 
with MA use disorder only accounted for 30% of the SUD group, and the study did not control for large differ-
ences in lifestyle and clinical confounders between individuals with SUDs and healthy controls.
MA use is associated with increases in production and alterations in gene expression of many 
pro-inflammatory cytokines6,47, which may contribute to neurological deficits, anxiety, and impaired mem-
ory48. Many of the bacterial genera that were elevated in MA users, such as Porphyromonas45, Veillonella49, 
and Fusobacterium50 have been correlated with increases in pro-inflammatory cytokines. MA also exacer-
bates systemic inflammation by damaging gastrointestinal barrier integrity and inducing permeability, allow-
ing the translocation of microbes and microbial products into the body. Our study identified depletions in 
the butyrate-producing genera Faecalibacterium and Butyricicoccus in MA users, which have been inversely 
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Figure 3. Comparisons of individual genera between methamphetamine (MA) users and non-users. Forest 
plots of results of zero-inflated negative binomial models comparing genus-level bacterial counts between 
methamphetamine (MA) users and non-users. Inverse probability of treatment-weighted effect sizes (log 
normalized count ratios) and false coverage rate (FCR)-adjusted 90% confidence intervals are plotted, with 
statistical significance (q < 0.1) indicated in black. Genera with no effect are not shown. Dots are sized 
proportionally to overall mean abundance across samples, i.e., genera with larger dots are, on average, more 
abundant.
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correlated with biomarkers of microbial translocation51,52. A study of patients with alcohol use disorder showed 
that those with higher levels of gut permeability had lower levels of Bifidobacterium and Faecalibacterium species 
and exhibited more symptoms of alcohol dependence and cravings53.
Emerging preclinical research has demonstrated a complex interplay between the microbiome and the central 
nervous system54, leading to inquiries about the role of dysbiosis in addiction pathology. Gut bacteria produce 
neuroactive substances, including serotonin, epinephrine and dopamine55, which may access the brain’s reward 
centers via gut-innervating vagal neurons56. Streptococcus, which was elevated in MA users in our study, can 
produce serotonin and Lactobacillus, which was depleted in MA users (in our biomarker analysis), can produce 
gamma-aminobutyric acid (GABA)55. Laboratory experiments of other drugs of abuse have suggested a connec-
tion between dysbiosis and addiction pathology. For example, increased sensitivity to cocaine reward through 
alterations in dopaminergic pathways has been observed in mice with experimentally disrupted microbiome57. 
Another study showed that manipulation of the microbiome resulted in several characteristics of opioid depend-
ence in mice, such as reduced opioid analgesic potency and impaired reward behavior58. In addition, there is 
some preclinical evidence that “repairing” the microbiome might alleviate addiction pathology, e.g., Lactobacillus 
species restored chemically-depressed dopamine levels in the prefrontal cortex when administered to rats as a 
probiotic59. However, these studies have not involved MA, and the preclinical connection between dysbosis and 
MA dependence is speculative.
In humans, potential mechanisms linking dysbiosis to the pathology of MA dependence remain largely unex-
plored. There is limited clinical evidence linking dysbiosis with symptoms associated with MA dependence, such 
altered stress response and increased depression. Butyrate-producing Faecalibacterium, which was decreased in 
MA users in our study, has been associated with reduced depression and higher quality of life60. Common symp-
toms of MA withdrawal, including depression, anxiety, and fatigue, have been correlated with imbalances in gut 
microbiota61, and probiotics have been used to successfully reduce anxiety and depression in clinical trials62. It 
is plausible that targeting dysbiosis may ease these symptoms among individuals undergoing treatment for MA 
use disorders.
We also found a number of genera that were impacted by MA which have previously been shown to play a role 
in HIV acquisition, disease progression, and pathogenesis. Increased abundances of Finegoldia and Peptoniphilus 
in the penile microbiome have been associated with elevated risk for HIV seroconversion in men63, and 
Parvimonas has been shown to increase genital tract inflammation64 and the risk of HIV acquisition in women65. 
The implications of enrichment of these bacteria in the rectal microbiome have not been explored; however, it is 
likely that inflammation exacerbated by dysbiosis underlies the increase in seroconversion risk, which would be 
highly relevant to at-risk MSM. We also found that MA use increased Fusobacterium, which has been correlated 
with decreased CD4+ T-cell count and increased T-cell activation in HIV+ individuals as well as reduced T-cell 
recovery following ART initiation66. HIV and MA interacted to multiplicatively increase Actinomyces, which may 
play a role in reactivating HIV in latently infected cells67. Parvimonas and Peptostreptococcus are oral pathogens 
that have been implicated in periodontal infections among HIV+ individuals68,69, and their damaging effects may 
be heightened in MA users due to MA’s proclivity to reduce saliva production. Finally, increased abundance of 
Veillonella has been linked with HIV-associated pulmonary diseases70. Our study, showing that MA impacted the 
relative abundance of each of these genera, may highlight mechanisms underlying the relationship between MA 
use, HIV acquisition and transmission risk, and HIV disease progression which warrant further investigation.
Our results should be interpreted considering the following limitations. Primarily, no diet data is collected 
for this cohort. We controlled for race/ethnicity and homelessness, which may impact diet and thus mitigate the 
effects of this limitation; however, we were unable to fully account for the effects of diet in our analyses. Using 
IPTW, our study accounts for a plethora of other clinical and behavioral confounders which may have masked 
true findings or generated spurious associations in previous studies. However, IPTW cannot achieve perfect 
balance between exposure groups in real-world research applications, and thus we cannot rule out residual con-
founding even by variables included in our analyses. Our study was also conducted in a cohort comprised entirely 
of MSM, all of whom were practicing anal intercourse, which increases internal validity by eliminating the effects 
of some important confounders (e.g. gender, sexual behavior). However, this may limit the generalizability of 
our findings to other groups, such as women who use MA. Finally, because the ability of 16 S gene sequencing to 
identify bacterial species is limited, we conducted our analyses at the genus level. We caution that differences in 
genera do not necessarily correspond to differences in functionally important species.
MA use remains a significant public health challenge, especially among people living with HIV. Our study 
found that MA use was associated with an imbalance in gut microbial composition favoring pro-inflammatory, 
potentially pathogenic bacteria, including some with neuroactive potential. There is currently no accepted phar-
maceutical treatment for MA use disorder and limited evidence for the effectiveness of cognitive-behavioral ther-
apy; further research into changes in the microbiome associated with MA use may inform therapeutic approaches 
for individuals with MA use disorder. Moreover, increases in multiple taxa that have been previously associated 
with poor HIV outcomes or HIV transmission and acquisition are particularly concerning in our study pop-
ulation of MSM who were either HIV-infected or at high risk for infection. Additional investigation into the 
mechanisms underlying these associations may improve HIV prognosis and prevent future infections among this 
vulnerable group.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request. All sequencing data has been deposited into BioProject with the accession number 
PRJNA422134.
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